{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:48:36Z","timestamp":1792090116778,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Northeastern University USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Trilaciclib, in comparison to placebo plus carboplatin, etoposide,\u2009\u00b1\u2009atezolizumab (PEA), has shown significant reductions in incidence of severe neutropenia (SN) among patients with extensive-stage small cell lung cancer (ES-SCLC). Despite these findings, real-world utility remains limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A single-center quasi-experimental study compared trilaciclib\u2009+\u2009PEA (PEAT) versus PEA in ES-SCLC patients. The study period ranged from April 1, 2021 to July 31, 2022, for the PEAT recipients and February 1, 2020, to February 28, 2021, for PEA recipients. The primary endpoint evaluated was incidence of SN after cycle 1 and during the treatment period. Secondary endpoints included measures related to myelopreservation and patient outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 34 PEAT and 44 PEA patients, baseline characteristics were similar, except for a higher median age (69 vs 64\u00a0years) and more males (64.7% vs 38.6%) in the PEAT cohort. The PEAT cohort exhibited a lower SN rate (3%) versus the PEA cohort (18%), with statistical significance demonstrated on multivariate analysis (<jats:italic>p<\/jats:italic>\u2009=\u20090.015). Additionally, the PEAT cohort also demonstrated significant reductions in red blood cell transfusion requirements (3% vs 23%; <jats:italic>p<\/jats:italic>\u2009=\u20090.02), grade 3\u20134 anemia (6% vs 25%; <jats:italic>p<\/jats:italic>\u2009=\u20090.03), and grade 3\u20134 thrombocytopenia (0% vs 11%, <jats:italic>p<\/jats:italic>\u2009=\u20090.045).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Trilaciclib, in combination with PEA, demonstrated an improvement in the safety profile without compromising survival outcomes in ES-SCLC patients. These findings underscore the potential benefits of incorporating trilaciclib in real-world clinical settings for enhanced patient care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-024-08828-1","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T12:03:07Z","timestamp":1725105787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?"],"prefix":"10.1007","volume":"32","author":[{"given":"Joseph","family":"Elijah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prantesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Holdsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Przespolewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristopher","family":"Attwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Billias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace K.","family":"Dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"issue":"6","key":"8828_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.21.01881","volume":"40","author":"J Zugazagoitia","year":"2022","unstructured":"Zugazagoitia J, Paz-Ares L (2022) Extensive-stage small-cell lung cancer: first-line and second-line treatment options. J Clin Oncol 40(6):671\u2013680. https:\/\/doi.org\/10.1200\/JCO.21.01881","journal-title":"J Clin Oncol"},{"issue":"23","key":"8828_CR2","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"issue":"10212","key":"8828_CR3","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6","journal-title":"Lancet"},{"issue":"4","key":"8828_CR4","first-page":"209","volume":"3","author":"S Kurtin","year":"2012","unstructured":"Kurtin S (2012) Myeloid toxicity of cancer treatment. J Adv Pract Oncol 3(4):209\u2013224","journal-title":"J Adv Pract Oncol"},{"issue":"3","key":"8828_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","volume":"93","author":"LJ Havrilesky","year":"2015","unstructured":"Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J (2015) A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol 93(3):203\u2013210. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.10.006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"8828_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1634\/theoncologist.5-3-224","volume":"5","author":"L Balducci","year":"2000","unstructured":"Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. Oncologist 5(3):224\u2013237. https:\/\/doi.org\/10.1634\/theoncologist.5-3-224","journal-title":"Oncologist"},{"issue":"1","key":"8828_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","volume":"1","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1(1):23\u201335. https:\/\/doi.org\/10.3816\/SCT.2003.n.002","journal-title":"Support Cancer Ther"},{"key":"8828_CR8","unstructured":"National Comprehensive Cancer Network.\u00a0Hematopoietic Growth Factors (Version 2.2022).\u00a0http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf. Accessed 15 Aug 2022"},{"issue":"10","key":"8828_CR9","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00520-016-3277-0","volume":"24","author":"Y Li","year":"2016","unstructured":"Li Y, Klippel Z, Shih X, Reiner M, Wang H, Page JH (2016) Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. Support Care Cancer 24(10):4377\u20134383. https:\/\/doi.org\/10.1007\/s00520-016-3277-0","journal-title":"Support Care Cancer"},{"issue":"5","key":"8828_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/1535-7163.MCT-15-0775","volume":"15","author":"JE Bisi","year":"2016","unstructured":"Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC (2016) Preclinical characterization of G1T28: a novel CDK4\/6 inhibitor for reduction of chemotherapy-induced myelosuppression. Mol Cancer Ther 15(5):783\u2013793. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0775","journal-title":"Mol Cancer Ther"},{"issue":"387","key":"8828_CR11","doi-asserted-by":"publisher","first-page":"eaal3986","DOI":"10.1126\/scitranslmed.aal3986","volume":"9","author":"S He","year":"2017","unstructured":"He S, Roberts PJ, Sorrentino JA et al (2017) Transient CDK4\/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Sci Transl Med. 9(387):eaal3986. https:\/\/doi.org\/10.1126\/scitranslmed.aal3986","journal-title":"Sci Transl Med."},{"issue":"2","key":"8828_CR12","doi-asserted-by":"publisher","first-page":"e000847","DOI":"10.1136\/jitc-2020-000847","volume":"8","author":"AY Lai","year":"2020","unstructured":"Lai AY, Sorrentino JA, Dragnev KH et al (2020) CDK4\/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer 8(2):e000847. https:\/\/doi.org\/10.1136\/jitc-2020-000847","journal-title":"J Immunother Cancer"},{"issue":"10","key":"8828_CR13","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","volume":"30","author":"JM Weiss","year":"2019","unstructured":"Weiss JM, Csoszi T, Maglakelidze M et al (2019) Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial. Ann Oncol 30(10):1613\u20131621. https:\/\/doi.org\/10.1093\/annonc\/mdz278","journal-title":"Ann Oncol"},{"issue":"10","key":"8828_CR14","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/ijc.33453","volume":"148","author":"D Daniel","year":"2020","unstructured":"Daniel D, Kuchava V, Bondarenko I et al (2020) Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled Phase II trial [published online ahead of print, 2020 Dec 21]. Int J Cancer 148(10):2557\u20132570. https:\/\/doi.org\/10.1002\/ijc.33453","journal-title":"Int J Cancer"},{"key":"8828_CR15","unstructured":"National Comprehensive Cancer Network.\u00a0Prevention and Treatment of Cancer-Related Infections (Version 2.2022).\u00a0http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf. Accessed 29 Aug 2022"},{"issue":"1","key":"8828_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. CTCAE versi\u00f3n 5.0. Evaluaci\u00f3n de la gravedad de los eventos adversos dermatol\u00f3gicos de las terapias antineopl\u00e1sicas. Actas Dermosifiliogr 112(1):90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"8828_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u201381","journal-title":"J Biomed Inform"},{"key":"8828_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN (2019) REDCap Consortium, The REDCap consortium: building an international community of software partners. J Biomed Inform. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"issue":"5","key":"8828_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","volume":"22","author":"J Weiss","year":"2021","unstructured":"Weiss J, Goldschmidt J, Andric Z et al (2021) Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase ii randomized, double-blind, placebo-controlled studies. Clin Lung Cancer 22(5):449\u2013460. https:\/\/doi.org\/10.1016\/j.cllc.2021.03.010","journal-title":"Clin Lung Cancer"},{"issue":"17","key":"8828_CR20","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1002\/cam4.4089","volume":"10","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Anderson I, Medgyasszay B et al (2021) Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: pooled analysis of three randomized phase 2 trials. Cancer Med 10(17):5748\u20135756. https:\/\/doi.org\/10.1002\/cam4.4089","journal-title":"Cancer Med"},{"issue":"1","key":"8828_CR21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12325-020-01538-0","volume":"38","author":"LL Hart","year":"2021","unstructured":"Hart LL, Ferrarotto R, Andric ZG et al (2021) Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther 38(1):350\u2013365. https:\/\/doi.org\/10.1007\/s12325-020-01538-0","journal-title":"Adv Ther"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08828-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08828-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08828-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T04:04:32Z","timestamp":1725249872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08828-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["8828"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08828-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,31]]},"assertion":[{"value":"16 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of Roswell Park Comprehensive Cancer Center approved this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"622"}}